Lupin receives FDA nod for generic vancocin capsules

Vancocin capsules had annual US sales of $ 164.2 million.

Lupin has received final approval for its vancomycin hydrochloride capsules, 125 mg and 250 mg from the US Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals, Inc’s Vancocin capsules, 125 mg and 250 mg strengths. Lupin Pharmaceuticals Inc. (LPI), the company’s US subsidiary would commence marketing the product shortly.

Lupin’s Vancomycin capsules 125 mg and 250 mg are the AB rated generic equivalent of ANI Pharmaceuticals Inc’s Vancocin capsules and are indicated for the treatment of C.difficile-associated diarrhoea and also for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).